The Advertising Standards Authority (ASA) has implemented a ban on social media posts that promote prescription-only weight-loss injections, marking a significant regulatory intervention in the digital advertising landscape. The posts in question, which included discount codes and referral links, were associated with online pharmacies such as Voy, Zava, MedExpress, and UK Meds Direct, and have now been deemed non-compliant with advertising regulations.
Regulatory Framework Around Prescription Medications
The ASA’s ruling underscores the stringent guidelines governing the advertising of prescription-only medications. Weight-loss injections, including the popular Mounjaro, are classified as prescription-only due to their potency and potential health risks. As such, they cannot be openly marketed to the public, particularly through platforms like Instagram, TikTok, and Facebook, where personal endorsements can easily blur the lines of professional medical advice.
Affiliate marketing schemes, which incentivise individuals to share referral links or discount codes, have come under scrutiny. The ASA highlighted that this practice can lead to unregulated promotion of prescription medicines, as individuals—often unaware of the implications—share content that may violate advertising laws. The authority clarified that both the brands and the individuals promoting these products bear responsibility for adhering to advertising standards.
Implications for Online Pharmacies and Influencers
The ASA’s decision sends a strong message to both online pharmacies and social media influencers. While companies such as Voy and Zava contend that they did not directly solicit these posts, the ASA determined that they still hold accountability for how their affiliate programmes are structured and managed. By controlling the mechanics of these referral schemes, they are indirectly facilitating the promotion of potentially dangerous medications without adequate medical oversight.
Catherine Drewett, the ASA’s investigations manager, stated, “Today’s rulings send a clear message that affiliate marketing is not a loophole and that promoting prescription medicines through social media, whether as a brand, influencer, or customer, is against the law and our rules.” The authority has emphasised its commitment to swift enforcement actions to protect consumers from irresponsible advertising practices.
Responses from Affected Companies
In the wake of the ASA’s announcement, affected parties have expressed their viewpoints. A spokesperson for Voy acknowledged that the posts were created independently by their customers in 2024 and noted that the company has since reinforced its controls surrounding referral activities. They reiterated that clinical decisions regarding medication suitability are strictly between patients and qualified clinicians, distancing themselves from any responsibility for the posts.
Zava also responded, asserting their dedication to compliance with regulatory standards. They expressed disappointment over the ruling, maintaining that they had no commercial ties with the social media users involved and underscoring their lack of control over independently shared content.
Wider Health and Safety Considerations
The ruling has received backing from healthcare regulatory bodies. Julian Beach, interim executive director at the Medicines and Healthcare products Regulatory Agency (MHRA), welcomed the ASA’s decisive actions, emphasising that prescription-only weight-loss medications should only be dispensed following comprehensive clinical assessments. Beach noted that the promotion of these drugs via social media undermines vital patient protection measures.
Dionne Spence, chief enforcement officer at the General Pharmaceutical Council (GPhC), reiterated the importance of adherence to advertising regulations, stating that online providers must ensure compliance in their marketing approaches, including those involving affiliate schemes.
Why it Matters
The ASA’s ban on the promotion of prescription-only weight-loss medicines through social media highlights a crucial intersection between digital marketing and healthcare regulations. As online platforms continue to grow as influential advertising avenues, the need for stringent oversight becomes increasingly evident. This ruling not only aims to safeguard public health but also serves as a critical reminder to businesses about the importance of ethical marketing practices. The potential risks associated with the misuse of potent medications demand a collective responsibility to maintain the integrity of health communications, ensuring that patient safety remains paramount.